In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 6, 2002, Pages 479-489

  Avramis, Ioannis A ^a   Christodoulopoulos, Garyfallia ^a   Suzuki, Atsushi ^a   Laug, Walter E ^a   Gonzalez Gomez, Ignacio ^a   McNamara, George ^a   Sausville, Edward A ^b   Avramis, Vassilios I ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Brain tumors; Leukemia; Tyrosine kinase; VEGF

Indexed keywords

ADAPHOSTIN; CASPASE 3; DNA; NSC 682494; PROTEIN BCL 2; PROTEIN P53; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RNA; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CAUDATE NUCLEUS; CELL ACTIVITY; CELL CLONE; CELL KILLING; CELL LINE; CELL PROLIFERATION; CELL STRAIN U937; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; LEUKEMIA CELL LINE; MOUSE; MYELOMONOCYTIC LEUKEMIA; NECROSIS; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PUTAMEN; SURVIVAL RATE; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING;

ADAMANTANE; ANIMALS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CASPASE 3; CASPASES; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FUSION PROTEINS, BCR-ABL; GLIOBLASTOMA; HUMANS; HYDROQUINONES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, T-CELL; LYMPHOKINES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036449307     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0507-6     Document Type: Article

References (35)

1. Aguayo A, O'Brien S, Keating M, Manshouri T, Gidel C, Barlogie B, Beran M, Koller C, Kantarjian H, Albitar M (2000) Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood 96:768-770
2. Antonsson BE, Avramis VI, Nyce J, Holcenberg JS (1987) Effect of 5-azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/0 and CCRF/CEM/dCk-1. Cancer Res 47:3672-3678
3. Avramis IA, Christodoulopoulos G, Kwock R, Sausville EA, Avramis VI (2001) NSC 680410 and NSC 642492: Novel anti-leukemic agents with activity in p53-null human leukemia cell lines in vitro (abstract 1015). Proc Am Assoc Cancer Res 42:189
4. Avramis IA, Kwock R, Avramis VI (2001) Taxotere and vincristine inhibit the secretion of the angiogenesis-inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines. Anticancer Res 21:2281-2286
5. Avramis VI, Wiersma S, Krailo MD, Ramilo-Torno LV, Sharpe A, Liu-Mares W, Kwock R, Reaman GH, Sato JK (1998) Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Clin Cancer Res 4:45-52
6. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100-104
7. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ (1997) CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90:4947-4952
8. Dinndorf PA, Avramis VI, Wiersma S, Krailo MD, Liu-Mares W, Seibel NL, Sato JK, Mosher RB, Kelleher JF, Reaman GH (1997) Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: A report from the Children's Cancer Group. J Clin Oncol 15:2780-2785
9. Finnie NJ, Gottlieb TM, Blunt T, Jeggo PA, Jackson SP (1995) DNA-dependent protein kinase activity is absent in xrs-6 cells: Implications for site-specific recombination and DNA double-strand break repair. Proc Natl Acad Sci U S A 92:320-324
10. Folkman J (1992) The role of angiogenesis in tumor growth. Semin Cancer Biol 3:58-61
11. Fu CH, Martin-Aragon S, Ardi V, Avramis VI (2000) The incidence of p53 and bcl-2 protein in leukemic blasts from pediatric patients with newly diagnosed leukemias and in relapse (abstract 2320). Proc Am Soc Clin Oncol 19:590a
12. Fusetti L, Pruneri G, Gobbi A, Rabascio C, Carboni N, Peccatori F, Martinelli G, Bertolini F (2000) Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: Frequency of apoptotic cells in solid tumors and effciency and speed of engraftment correlate with vascular endothelial growth factor production. Cancer Res 60:2527-2534
13. Horita M, Andreu EJ, Benito A, et al (2000) Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 191:977-984
14. Hynes RO (1987) Integrins: A family of cell surface receptors Cell 48:549-554
15. Kaur G, Gazit A, Levitzki A, Stowe E, Cooney DA, Sausville EA (1994) Tyrphostin induced growth inhibition: Correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anticancer Drugs 5:213-222
16. Kini AR, Kay NE, Peterson LC (2000) Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 14:1414-1418
17. Kini AR, Peterson LC, Tallman MS, Lingen MW (2001) Angiogenesis in acute promyelocytic leukemia: Induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood 97:3919-3924
18. Koomagi R, Zintl F, Sauerbrey A, Volm M (2001) Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clin Cancer Res 7:3381-3384
19. Krystal GW, Honsawek S, Kiewlich D, Liang C, Vasile S, Sun L, McMahon G, Lipson KE (2001) Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res 61:3660-3668
20. Lam V, McPherson JP, Salmena L, Lees J, Chu W, Sexsmith E, Hedley DW, Freedman MH, Reed JC, Malkin D, Goldenberg GJ (1999) p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leuk Res 23:871-880
21. MacDonald TJ, Tabrizi P, Shimada H, Zlokovic BV, Laug WE (1998) Detection of brain tumor invasion and micrometastasis in vivo by expression of enhanced green fluorescent protein. Neurosurgery 43:1437-1442; discussion 1442-1443
22. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, Laug WE (2001) Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 48:151-157
23. Majlessipour F, Kwock R, Martin-Aragon S, Weinberg KI, Avramis VI (2001) Development of a double-drug-resistant human leukemia model to cytosine arabinoside and L-aspara-ginase: Evaluation of cross-resistance to other treatment modalities. Anticancer Res 21:11-22
24. Martin-Aragon S, Mukherjee SK, Taylor BJ, Ivy SP, Fu CH, Ardi VC, Avramis VI (2000) Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs. Anticancer Res 20:139-150
25. Mow BM, Chandra J, Svingen PA, Hallgreen CG, Weisberg E, Kottke TJ, Narayanan VL, Litzow MR, Griffin JD, Sausville EA, Tefferi A, Kaufmann SH (2002) Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 99:664-671
26. Nandy P, Lien EJ, Avramis VI (1994) Antileukemic activity studies and cellular pharmacology of the analogues of 2-hydroxy-1H-isoindole-1,3-dione (HISD) alone and in combination with cytosine arabinoside (ara-C) against human leukemia cells CEM/0. Acta Oncol 33:953-961
27. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Kohn KW (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300
28. Ozkaynak MF, Avramis VI, Carcich S, Ortega JA (1998) Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia. Med Pediatr Oncol 31:475-482
29. Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, Buchner T, Berdel WE, Mesters RM (2000) Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95:2637-2644
30. Pease AC, Solas D, Sullivan EJ, Cronin MT, Holmes CP, Fodor SP (1994) Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc Natl Acad Sci U S A 91:5022-5026
31. Powell WC, Avramis VI (1988) Biochemical pharmacology of 5,6-dihydro-5-azacytidine (DHAC) and DNA hypomethylation in tumor (L1210)-bearing mice. Cancer Chemother Pharmacol 21:117-121
32. Sambrook JC, Fritsch EF, Maniatis T (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor
33. Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B (1995) Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86:726-736
34. Srivastava RK, Srivastava AR, Cho-Chung YS, Longo DL (1999) Synergistic effects of retinoic acid and 8-Cl-cAMP on apoptosis require caspase-3 activation in human ovarian cancer cells. Oncogene 18:1755-1763
35. Svingen PA, Tefferi A, Kottke TJ, Kaur G, Narayanan VL, Sausville EA, Kaufmann SH (2000) E3ects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin Cancer Res 6:237-249